• Company
  • |
  • NEWS
  • |
  • Research and Development
  • |
  • Therapeutic Areas
  • |
  • Careers
  • |
  • Investor Area
  • |
  • Contact Us
  • |
  • 中文

Announcements
  • 2020-09-02  EASL 2020 (JKB-122 in Patients with Non-alcoholic Fatty Liver: A Phrase 2 Randomized Double-Blind Placebo-Control Study)
  • 2020-06-19  TaiwanJ Pharmaceuticals signed up an MTA with Merck healthcare KGaA (FWB:MRK)
  • 2019-03-08  TaiwanJ Pharmaceuticals Obtained US$26M Deal for Licensing and Co-Development Contract with Newsoara Biopharma on JKB-122 Asian Rights
  • 2019-01-22  TaiwanJ Pharmaceuticals Announces Positive Results from Phase 2 Orphan Drug Designation Study of JKB-122 on Autoimmune Hepatitis (AIH)
  • more
Pipeline
JKB-122
TJC0265
TJC0434
TJC0545
TJC0667
...
Core Technology
TLR4
Autotaxin
NOX
HDAC
...
Company| NEWS| Research and Development| Therapeutic Areas| Careers| Investor Area| Contact Us|
Address: Rm. 4, 3F, NO.6-1, Sec.2, ShengYi Rd., Zhubei City, Hsinchu County 302058, Taiwan (R.O.C) (Hsinchu Biomedical Science Park)   Phone: 03-6587721   E-MAIL: info@taiwanj.com    Fax:03-6587787